Matteo Pagnesi

Dr. Matteo Pagnesi

ASST Spedali Civili di Brescia
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2020 in Heart
Verified
Journal Article
Open access
PDF file
MPMatteo Pagnesi
Matteo Pagnesi
LBLuca Baldetti
Luca Baldetti
ABAlessandro Beneduce
Alessandro Beneduce
FCFrancesco Calvo
Francesco Calvo
MGMario Gramegna
Mario Gramegna
ACAlberto Maria Cappelletti
Alberto Maria Cappelletti
Objective To assess the prevalence, characteristics and prognostic value of pulmonary hypertension (PH) and right ventricular dysfunction (RVD) in hospitalised, non-intensive care unit (ICU) patients with coronavirus disease 2019 (COVID-19). Methods This single-centre, observational, cross-sectional study included 211 patients with COVID-19 admitted to non-ICU departments who underwent a single transthoracic echocardiography (TTE). Patients with poor acoustic window (n=11) were excluded. Clinical, imaging, laboratory and TTE findings were compared in patients with versus without PH (estimated systolic pulmonary artery pressure >35 mm Hg) and with versus without RVD (tricuspid annular plane systolic excursion <17 mm or S wave <9.5 cm/s). The primary endpoint was in-hospital death or ICU admission. Results A total of 200 patients were included in the final analysis (median age 62 (IQR 52–74) years, 65.5% men). The prevalence of PH and RVD was 12.0% (24/200) and 14.5% (29/200), respectively. Patients with PH were older and had a higher burden of pre-existing cardiac comorbidities and signs of more severe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (radiological lung involvement, laboratory findings and oxygenation status) compared with those without PH. Conversely, patients with RVD had a higher burden of pre-existing cardiac comorbidities but no evidence of more severe SARS-CoV-2 infection compared with those without RVD. The presence of PH was associated with a higher rate of in-hospital death or ICU admission (41.7 vs 8.5%, p<0.001), while the presence of RVD was not (17.2 vs 11.7%, p=0.404). Conclusions Among hospitalised non-ICU patients with COVID-19, PH (and not RVD) was associated with signs of more severe COVID-19 and with worse in-hospital clinical outcome. Trial registration number NCT04318366

29 May 2023 in JACC
Verified
Journal Article
Closed access
MPMatteo Pagnesi
Matteo Pagnesi
MMMarco I. Metra
Marco I. Metra
ACAlain Cohen-Solal
Alain Cohen-Solal
CEChristopher Edwards
Christopher Edwards
MAMarianna Adamo
Marianna Adamo
BDBeth Davison
Beth Davison

1 October 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
MPMatteo Pagnesi
Matteo Pagnesi
EMEnrico A. Martino
Enrico A. Martino
MCMauro Chiarito
Mauro Chiarito
AMAntonio Mangieri
Antonio Mangieri
RJRichard J. Jabbour
Richard J. Jabbour
Azeem LatibAzeem Latib
Azeem Latib

1 August 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
MPMatteo Pagnesi
Matteo Pagnesi
Claudio MontaltoClaudio Montalto
Claudio Montalto
AMAntonio Mangieri
Antonio Mangieri
EAEustachio Agricola
Eustachio Agricola
RPRishi Puri
Rishi Puri
Azeem LatibAzeem Latib
Azeem Latib

19 July 2023 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
MPMatteo Pagnesi
Matteo Pagnesi
WKWon-Keun Kim
Won-Keun Kim
SBSara Baggio
Sara Baggio
Andrea ScottiAndrea Scotti
Andrea Scotti
MBMarco Barbanti
Marco Barbanti
AMAntonio Mangieri
Antonio Mangieri

23 June 2021 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
MPMatteo Pagnesi
Matteo Pagnesi
MAMarianna Adamo
Marianna Adamo
ISIziah E. Sama
Iziah E. Sama
Stefan D. AnkerStefan D. Anker
Stefan D. Anker
JCJohn George Franklin Cleland
John George Franklin Cleland
MMMarco I. Metra
Marco I. Metra
Aims: Few data regarding the prevalence and prognostic impact of mitral regurgitation (MR) in patients with worsening chronic or new‐onset acute heart failure (HF) are available. We investigated the role of MR in the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT‐CHF). Methods and results: We performed a retrospective post‐hoc analysis including patients from both the index and validation BIOSTAT‐CHF cohorts with data regarding MR status. The primary endpoint was a composite of all‐cause death or HF hospitalization. Among 4023 patients included, 1653 patients (41.1%) had moderate–severe MR. Compared to others, patients with moderate–severe MR were more likely to have atrial fibrillation and chronic kidney disease and had larger left ventricular (LV) dimensions, lower LV ejection fraction (LVEF), worse quality of life, and higher plasma concentrations of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). A primary outcome event occurred in 697 patients with, compared to 836 patients without, moderate–severe MR [Kaplan–Meier 2‐year estimate: 42.2% vs. 35.3%; hazard ratio (HR) 1.28; 95% confidence interval (CI) 1.16–1.41; log‐rank P < 0.0001]. The association between MR and the primary endpoint remained significant after adjusting for baseline variables and the previously validated BIOSTAT‐CHF risk score (adjusted HR 1.11; 95% CI 1.00–1.23; P = 0.041). Subgroup analyses showed a numerically larger impact of MR on the primary endpoint in patients with lower LVEF, larger LV end‐diastolic diameter, and higher plasma NT‐proBNP. Conclusions: Moderate–severe MR is common in patients with worsening chronic or new‐onset acute HF and is strongly associated with outcome, independently of other features related to HF severity.